Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Creative Medical Technology and Silence Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| Silence Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 516.36%. Given Silence Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Creative Medical Technology.
Profitability
This table compares Creative Medical Technology and Silence Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
| Silence Therapeutics | -8,943.86% | -106.94% | -47.99% |
Insider and Institutional Ownership
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Creative Medical Technology and Silence Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $3,000.00 | 1,628.47 | -$5.99 million | ($2.07) | -0.36 |
| Silence Therapeutics | $560,000.00 | 933.25 | -$88.61 million | ($1.28) | -6.78 |
Creative Medical Technology has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Creative Medical Technology has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Summary
Silence Therapeutics beats Creative Medical Technology on 9 of the 15 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
